• Mashup Score: 0

    Over 60% of participants achieved the weight-reduction target of 20% or higher and had improved body composition in a phase 3 trial of tirzepatide in overweight/obesity.

    Tweet Tweets with this article
    • ICYMI: 'Staggering' #WeightLoss With #Tirzepatide https://t.co/QciU3Ht5tw via @medscape #Mounjaro "Something we have sought for decades, we have finally been able to achieve" #GIP + #GLP1

  • Mashup Score: 1

    A novel glucagon/GLP-1 receptor agonist conferred nearly 15% weight loss at 46 weeks among people with overweight or obesity without type 2 diabetes, according to an industry press release. In a phase 2 clinical trial, participants with overweight or obesity and no diagnosis of type 2 diabetes were randomly assigned to subcutaneous BI 456906 (Boehringer Ingelheim and Zealand Pharma) or placebo

    Tweet Tweets with this article
    • Adults with obesity lose nearly 15% of body weight with glucagon/GLP-1 receptor agonist #GLP1 #ozempic #wegovy #mounjaro #semaglutide #gip #tirzepatide https://t.co/sF2lrrXeNk

  • Mashup Score: 0

    A gastric inlet patch (GIP) is an island of heterotopic gastric mucosa found commonly in the proximal oesophagus just below the upper oesophageal sphincter. It is often underdiagnosed due to its location. Its importance and clinical relevance can be underestimated [1]. It is important to recognise as these patients can present to general practice, gastroenterology or ENT clinics with a wide…

    Tweet Tweets with this article
    • Did you know that a gastric inlet patch (#GIP) can cause a wide variety of persistent throat symptoms? Don't underestimate the clinical relevance of this underdiagnosed condition. Our latest article discusses the importance of recognizing and treating it https://t.co/kkDV3ACXCK

  • Mashup Score: 12

    Abstract. As heart failure (HF) enters a new era with high level of evidence supporting the use of individual drug therapies, we put forth a rationale for the n

    Tweet Tweets with this article
    • The last decade established building blocks of #CaReMe. The next will drive implementation & test different drugs in combo. T2D: #SGLT2i + #GLP1RA HF & CKD: #SGLT2i + #MRA Obesity: #GLP1 + #GIP + #Glucagon Super⭐️@vbluml discusses in @escardio #EHJSuppl https://t.co/MiPfvDExIR https://t.co/hlwGQsxAuA

  • Mashup Score: 13

    In the summer of 2018, Lisa Robillard left her doctor’s office and walked down the long corridor of a medical complex in suburban Virginia. She’d just had an appointment with yet another physician who could only recommend “diet and exercise” when she brought up her life-long struggle with her weight.

    Tweet Tweets with this article
    • A new ‘miracle’ weight-loss drug really works — raising huge questions - it’s no miracle but #science - increasing #glp1 and #gip result in #weightloss and may be a reversal of the #weightgain process that causes #obesity @FT https://t.co/f7UYbF0IZL

  • Mashup Score: 1

    A 56-year-old man presented with a change in bowel habit to seven loose non-bloody stools a day. He had previously had a sigmoid resection for an endoscopic diagnosis of colonic malignancy in 2015. Histology of the resection specimen, however, had only shown inflammatory polyps, attributed to the accompanying diverticular disease. His current colonoscopy showed two malignant looking lesions in…

    Tweet Tweets with this article
    • Interesting #GUTSnapshot #GISnapshot in the current issue of @Gut_BMJ, on "Recurrent colonic polyps" by Aslan J, Conley T, Smith PJ, Subramanian S et al via https://t.co/YmSe9mexHB #GUTImage #GIP #polyposis @emadelomar @Philip_J_Smith @FrontGastro_BMJ https://t.co/HfMWDTlxXq